<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10267">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677534</url>
  </required_header>
  <id_info>
    <org_study_id>11225</org_study_id>
    <nct_id>NCT00677534</nct_id>
  </id_info>
  <brief_title>Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease</brief_title>
  <official_title>Exploring the Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the role of nutritional Vitamin D deficiency as a
      potential contributor to the morbidity witnessed in patients with end-stage renal disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goals of this study are to elucidate the function of extrarenal 1 alpha-hydroxylase
      activity in the setting of renal failure and to evaluate the role of nutritional vitamin D
      deficiency as a potential contributor to monocyte-associated inflammatory pathways in
      patients with end-stage renal disease (ESRD). This study will consist of patients on chronic
      maintenance hemodialysis three times per week who have been identified to have nutritional
      vitamin D deficiency. After consent for study enrollment, patients will undergo a 4 week
      washout period of all active vitamin D supplementation. After washout is complete, an blood
      sample will be obtained for baseline 25(OH)D levels and monocyte isolation for analysis by
      flow cytometry. Patients will then be started on cholecalciferol 50,000 IU twice weekly for
      8 weeks. 25-vitamin D levels will be monitored midway through the treatment phase of the
      study and dosing adjusted as further described in detail within the protocol section. An
      additional blood sample will be drawn post-therapy for repeat 25(OH)D levels and monocyte
      isolation for flow cytometry analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Monocyte VDR Expression With Vitamin D Therapy</measure>
    <time_frame>Change from End of Washout to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Monocytes will be analyzed pre- and post-cholecalciferol by flow cytometry to measure changes in monocyte VDR expression. Unit of measure is represented by mean florescence intensity (MFI), which is a relative measure.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>End-Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholecalciferol (Vitamin D)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>50,000 Units PO Twice weekly for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Vitamin D, ergocalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  End-stage renal disease undergoing maintenance hemodialysis at KUMC outpatient
             hemodialysis unit

          -  Dialysis vintage of at least 6 months duration

          -  Nutritional vitamin D deficiency, defined as 25(OH)D &lt;25 ng/ml

          -  Age 21 to 88 years

        Exclusion Criteria:

          -  Active infection

          -  Recent hospitalization for acute illness (within last 1 month)

          -  Refusal to study participation

          -  Poorly controlled secondary hyperparathyroidism (iPTH&gt;500)

          -  History of chronic inflammatory disease process, such as inflammatory bowel,
             rheumatoid arthritis, lupus, etc.

          -  Cinacalcet therapy

          -  Previous allergy to ergocalciferol

          -  History of parathyroidectomy

          -  Current treatment with immunosuppressant medications

          -  Noncompliance with prescribed hemodialysis regimen (i.e. skipping treatments, ending
             sessions early)

          -  Functional renal transplant within the last five years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Stubbs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <results_reference>
    <citation>Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol. 2010 Feb;21(2):353-61. doi: 10.1681/ASN.2009040451. Epub 2009 Dec 10.</citation>
    <PMID>20007751</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>May 12, 2008</firstreceived_date>
  <firstreceived_results_date>June 11, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas</investigator_affiliation>
    <investigator_full_name>Jason Stubbs, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Endstage renal disease</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Monocyte function</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cholecalciferol 50,000 U</title>
          <description>Vitamin D</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Washout (Weeks 1-4)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>did not qualify after signing consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Cholecalciferol (Weeks 5-12)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>After Paricalcitol Restart (Weeks 13-14)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 11 subjects were consented to the study. 1 subject was hospitalized before starting any procedures and did not complete any study procedures. 1 subject did not qualify for the study after consenting. Two subjects withdrew after consenting.</population>
      <group_list>
        <group group_id="B1">
          <title>Cholecalciferol 50,000 U</title>
          <description>Vitamin D</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Monocyte Vitamin D receptor (VDR) expression</title>
          <units>MFI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="572.7" spread="172.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Monocyte VDR Expression With Vitamin D Therapy</title>
        <description>Monocytes will be analyzed pre- and post-cholecalciferol by flow cytometry to measure changes in monocyte VDR expression. Unit of measure is represented by mean florescence intensity (MFI), which is a relative measure.</description>
        <time_frame>Change from End of Washout to Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Clinical pilot trial - proof of concept</population>
        <group_list>
          <group group_id="O1">
            <title>Cholecalciferol 50,000 U</title>
            <description>Vitamin D</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Monocyte VDR Expression With Vitamin D Therapy</title>
            <description>Monocytes will be analyzed pre- and post-cholecalciferol by flow cytometry to measure changes in monocyte VDR expression. Unit of measure is represented by mean florescence intensity (MFI), which is a relative measure.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1899" spread="644.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cholecalciferol 50,000 U</title>
          <description>Vitamin D</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a pilot study using a small number of patients. Further studies are needed to validate these findings in larger groups of patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jason Stubbs</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-3867</phone>
      <email>jstubbs@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
